Skip to main content

Table 5 Difference analysis results

From: Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

 

Responders

(N = 21)

Non-responders

(N = 59)

Mean differencea

Mean change from baseline (95% CI)

Mean change from baseline (95% CI)

(95% CI)

p-value

Total FACT-MM

−1.72 (−13.63 to 10.20)

−12.89 (−19.18 to −6.60)

11.17 (−2.30 to 24.65)

p = 0.104

FACT-G

−3.05 (−8.90 to 2.79)

−10.28 (−14.13 to −6.42)

7.22 (0.22 to 14.22)

p = 0.043

FACT-MM TOI

−4.33 (−14.11 to 5.44)

−10.60 (−15.84 to −5.35)

6.26 (−4.82 to 17.35)

p = 0.268

MM Domain

2.57 (−3.05 to 8.19)

−2.16 (−5.60 to 1.27)

4.73 (−1.85 to 11.32)

p = 0.159

  1. FACT-G Functional Assessment of Cancer Therapy – General, FACT-MM Functional Assessment of Cancer Therapy – Multiple Myeloma, MM multiple myeloma, TOI Trial Outcomes Index, CI confidence interval
  2. a Difference analysis between baseline and end of treatment in responders compared to non-responders as estimated by a mixed effects model
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us